drugset / Trial / NCT01289119

Efficacy and Safety of Alogliptin in Participants With Type 2 Diabetes

NCT01289119

Phase 3 Completed 506 enrolled Takeda
RandomizedParallel-groupQuadruple-blindTreatment

Summary

The purpose of the study is to determine the efficacy of alogliptin compared to placebo when given alone or as add-on therapy to metformin or add-on to pioglitazone (with or without metformin).

Timeline

Start
2010-12
Primary completion
2011-12
Completion
2011-12

Drugs

EvaluationDrugModalityDoseRoute
Subject Alogliptin Unknown 25 mg Oral
Background Metformin Small molecule
Background Pioglitazone Small molecule